Sequencing
Founded 2017 · 48 employees on LinkedIn · 6 known investors
Sequencing.com offers free storage of personal DNA data along with tools and reports that turn genetic testing results into health-related insights for consumers. The company addresses data storage, usability, and privacy challenges created by widely available consumer genetic testing.
Also known as Sequencing.com
Founders & leadership
Sequencing was founded in 2017 by Brandon Colby.


Investors · 6
Also in the syndicate · 2
Company profile
researched Aug 2026Sequencing.com is a direct-to-consumer DNA interpretation company that sells at-home genetic testing kits and turns genomic data into health, wellness and ancestry reports. Its core offering is 30x whole genome sequencing from a saliva or cheek-swab collection kit, covering approximately 3 billion genomic positions and reporting single nucleotide polymorphisms, insertions and deletions, structural variations, copy number variations and mitochondrial heteroplasmy. Customers can download raw and analyzed data files (FASTQ, BAM, VCF) at no additional fee. As an alternative to buying a kit, users can upload or import raw DNA data generated by other testing services such as 23andMe and Ancestry.com and have it analyzed on the platform.
On top of testing, the company operates a marketplace of DNA apps and reports, both first-party and third-party, spanning categories including health, ancestry, nutrition, fitness, beauty, lifestyle, children, bioinformatics, clothing and art. Reviewers have counted over 100 apps, priced from free to several hundred dollars, with examples including Carrier Status ($29), Genetic Ancestry With Haplogroups ($59), DNA Diet ($59), Inherited Traits Genetic Analysis ($129), Genetic Counseling ($179), Wellness & Longevity ($199) and an Alzheimer's DNA Screen WGS Bundle ($449). Proprietary applications include Genome Explorer, a browser and search engine for a customer's genome, and Next-Gen Rare Disease Screen, which screens for the risk of thousands of rare diseases, conditions and traits. The company also markets an optional subscription under which a customer's genome is periodically reanalyzed against newly published research without additional testing.
Founding story
The company was founded by Dr. Brandon Colby, a physician who holds an MD from the Mount Sinai School of Medicine and wrote a book on predictive medicine and genetics, "Outsmart Your Genes."
Business model
Sells one-time DNA testing kits and bundles, individually priced reports and apps through a marketplace, and recurring memberships that bundle data storage, report credits, alerts and access to licensed genetic counselors. Free DNA data upload and storage act as an entry point to paid analyses.
Product sales (test kits and bundles, for example a $399 whole genome sequencing kit and a $69 genotyping test), à la carte purchases of reports and apps, and tiered monthly subscriptions (reviewers cite Silver $9.99, Gold $29.99 and Platinum $49.99 per month in 2022, and membership starting at $19 per month in 2024).
Traction
Reviewers report an app marketplace with more than 100 apps and support for raw data formats from many genetic testing companies. Published customer reviews describe results turnaround of roughly four to eight weeks and use of whole genome results in clinical decision-making, while critics note added costs for third-party reports, absence of native relative matching, variable third-party report quality and occasional reports with unreportable results due to missing data.
Latest developments
As of its current website the company markets a Rare Disease Carrier Screen whole genome sequencing bundle at $399 (with a $999 ultra-rapid option), AI-generated reports, risk assessment across 15,000+ diseases, conditions and traits, and an optional subscription providing monthly reanalysis of the stored genome.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
Positioned in the direct-to-consumer genomics market alongside array-based testers such as 23andMe and Ancestry and whole-genome providers such as Nebula Genomics and Nucleus, differentiating on whole genome coverage and breadth of third-party report options. Reviewers describe its DNA app store as the largest of its kind.
Combines whole genome sequencing with an open third-party app and report marketplace, free unlimited storage and upload of DNA data from other providers, downloadable raw data at no extra cost, and a stated policy of never selling or sharing customer data, backed by HIPAA and US-EU Privacy Shield compliance claims.
Technology
30x whole genome sequencing performed in a CLIA-certified and CAP-accredited laboratory, covering effectively the whole genome versus the small fraction read by array-based consumer tests. The platform supports import of raw data files from many consumer genetic testing companies, hosts an app marketplace with an open API and open-source code, and provides Genome Explorer for genome browsing and search plus Next-Gen Rare Disease Screen for rare disease risk analysis. Subscription customers receive automated reanalysis of stored genomes as research databases are updated.
Go-to-market
Direct-to-consumer online sales of kits and bundles via its website, with free data upload and free apps used to attract users into paid reports and subscriptions, supported by email marketing and customer testimonials.
Consumers seeking health, wellness, pharmacogenomic, rare disease, family planning and ancestry insights from their DNA, including people who have already tested with other consumer genetics services and want deeper analysis of their existing raw data.
Geography
United States-based operations; reviewers place the company in Los Angeles and Pasadena, California. At-home kits are offered subject to availability in the customer's location.
History
Under CEO Dr. Brandon Colby, the company built a consumer platform combining DNA testing, free data upload and storage, and a marketplace of DNA apps. In November 2022 it raised $5 million led by Lerer Hippeau to enhance its DNA technology, around the time it upgraded its Genome Explorer and Next-Gen Rare Disease Screen applications. Its team comprises US medical doctors, geneticists, bioinformatics experts and software developers.
Risks & controversies
Third-party reviews cite the high cumulative cost of memberships and individually priced apps, reliance on third-party report providers of varying quality with few sample reports available, potential for overlapping or contradictory information across reports, lack of lifestyle factors in risk analyses, no native relative matching for ancestry, and user accounts of reports omitting results for certain conditions because of insufficient data.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 3
by search overlapCompanies competing with Sequencing for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 2
launches, deals, and filingsThe Los Angeles-based direct-to-consumer DNA interpretation company raised $5 million, led by Lerer Hippeau with participation from Red Sea Ventures, Global Founders Capital, XRC Labs, Correlation Ventures, Red Antler, Mucker Capital and Gaingels, to build upon and enhance its DNA technology.
$5M source ↗
The company upgraded two proprietary applications: Genome Explorer, an online browser and search engine for genomes that surfaces research relevant to a customer's DNA data, and Next-Gen Rare Disease Screen, which screens a genome for risk of thousands of rare diseases, conditions and traits.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
▸Research sources · 8
primary sources listed
- Sequencingsequencing.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Sequencing do?
- Consumer genomics company selling at-home whole genome sequencing plus a marketplace of DNA reports and apps.
- Who founded Sequencing?
- Sequencing was founded by Brandon Colby in 2017.
- Who are Sequencing's investors?
- Sequencing's investors include Expansion Venture Capital, Mucker Capital, XRC, Red Sea Ventures.



